AZP-531 is primarily investigated for its potential therapeutic applications in metabolic disorders, particularly in managing conditions like obesity and type 2 diabetes. It functions by modulating the activity of unacylated ghrelin, a hormone involved in regulating glucose metabolism and energy balance. Clinical studies have explored its efficacy in improving insulin sensitivity, reducing body weight, and controlling blood sugar levels in patients. Additionally, AZP-531 shows promise in addressing complications associated with metabolic syndrome, such as cardiovascular risks. Its unique mechanism of action makes it a candidate for innovative treatments in the field of metabolic health.